Michael Weiss MD, Director of the Neuromuscular Diseases Division of the University of Washington School of Medicine, discusses an upcoming phase II clinical trial that puts mexiletine to the test in ALS, a potential early treatment of the disease. Read more: http://blogs.als.net/post/2013/02/05/Mexiletine-channeling-ALS.aspx